Xenon Pharmaceuticals Inc. XENE
Xenon Pharmaceuticals Inc. statistics & valuation
Market cap$5.0B
P / B8.6×
Net margin-4612.1%
Return on equity-59.5%
FCF margin-3732.2%
Return on capital-63.1%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -4974.3% | — | — | -1368.9% | -428.4% | -97.3% | -627.0% | — | -10474.3% | -1376.4% |
| Net margin | -4612.1% | — | — | -1328.9% | -427.8% | -89.7% | -609.1% | — | -9872.7% | -1275.5% |
| FCF margin | -3732.2% | — | — | -1101.6% | -388.1% | -157.8% | -87.2% | — | -9337.9% | -1100.7% |
| Return on assets | -54.6% | -29.4% | -18.9% | -16.6% | -13.8% | -15.2% | -28.2% | -28.2% | -66.6% | -34.1% |
| Return on equity | -59.5% | -31.0% | -19.7% | -17.4% | -14.3% | -16.8% | -45.2% | -33.4% | -85.4% | -36.0% |
| Debt / equity | — | — | — | — | — | — | 0.12× | 0.15× | 0.17× | — |
| Current ratio | 13.42 | 17.85 | 23.65 | 26.44 | 39.03 | 12.30 | 3.34 | 29.46 | 10.98 | 18.31 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.